Clinical Trials Sponsored by Adiga Life Sciences

Total 831 results

Circassia Limited
Adiga Life Sciences, Inc.

Completed

Ragweed-SPIRE Follow-On Study

Rhinoconjunctivitis | Ragweed Allergy

Canada
Circassia Limited
Adiga Life Sciences, Inc.

Completed

Study of Grass-SPIRE in Subjects With Grass Allergies and Asthma

Asthma | Seasonal Allergic Rhinitis

Canada
Circassia Limited
Adiga Life Sciences, Inc.

Completed

Safety and Tolerability of ToleroMune Grass in Grass Allergic Subjects With Rhinoconjunctivitis

Allergy

Canada
Circassia Limited
Adiga Life Sciences, Inc.

Completed

Safety of ToleroMune Ragweed to Treat Ragweed Allergy in Ragweed Allergic Subjects With Rhinoconjunctivitis

Allergy

Canada
Circassia Limited
Adiga Life Sciences, Inc.

Completed

ToleroMune House Dust Mite (HDM) Tolerability Study

Rhinoconjunctivitis

Canada
Circassia Limited
Adiga Life Sciences, Inc.

Completed

Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis

Cat Allergy

Canada
Circassia Limited
Adiga Life Sciences, Inc.

Completed

Safety of ToleroMune House Dust Mite (HDM) to Treat House Dust Mite Allergy in HDM Allergic Subjects With Rhinoconjunctivitis

Allergy

Canada
Adiga Life Sciences, Inc.
Circassia Limited

Terminated

Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America

Allergy

United States
Circassia Limited
Adiga Life Sciences, Inc.

Completed

Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber

Seasonal Allergic Rhinitis

Canada
Circassia Limited
Adiga Life Sciences, Inc.

Completed

Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma

Asthma | Seasonal Allergic Rhinitis

Canada
Circassia Limited
Adiga Life Sciences, Inc.

Completed

ToleroMune Grass Follow on Study

Grass Allergy | Rhinoconjunctivitis

Canada
Circassia Limited
Adiga Life Sciences, Inc.

Completed

Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis

Cat Allergy

Canada
Circassia Limited
Adiga Life Sciences, Inc.

Completed

Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma

Cat Allergy

Canada
Circassia Limited
Quintiles, Inc.; Adiga Life Sciences, Inc.

Completed

Birch-SPIRE Safety and Efficacy Study

Rhinitis

Canada
Circassia Limited
Adiga Life Sciences, Inc.; Topstone Research

Completed

An Optional Investigation of Biomarkers of Efficacy

Rhinoconjunctivitis

Canada
Circassia Limited
Adiga Life Sciences, Inc.; Pharm-Olam International

Completed

ToleroMune Grass Exposure Unit Study

Grass Allergy | Rhinoconjunctivitis

Canada
Circassia Limited
Adiga Life Sciences, Inc.; Pharm-Olam International

Completed

ToleroMune Grass Follow on Study

Grass Allergy | Rhinoconjunctivitis
Circassia Limited
Adiga Life Sciences, Inc.; Inflamax Research Incorporated

Completed

ToleroMune House Dust Mite Follow on Study

Rhinoconjunctivitis | House Dust Mite Allergy
Circassia Limited
Adiga Life Sciences, Inc.; Cetero Research, Toronto

Completed

An Optional Two Year Follow Up Study to Study CP005A

Cat Allergy | Rhinoconjunctivitis

Canada
Circassia Limited
Cetero Research, San Antonio; Adiga Life Sciences, Inc.

Completed

Cat-PAD Exposure Chamber Study

Cat Allergy

Canada
Circassia Limited
Cetero Research, San Antonio; Adiga Life Sciences, Inc.

Completed

ToleroMune House Dust Mites (HDM) Exposure Chamber Study

Rhinoconjunctivitis

Canada
Circassia Limited
Cetero Research, San Antonio; Adiga Life Sciences, Inc.

Completed

ToleroMune Ragweed Exposure Chamber Study

Ragweed Allergy

Canada
Circassia Limited
Cetero Research, San Antonio; Adiga Life Sciences, Inc.

Completed

Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy

Ragweed Allergy

Canada
Circassia Limited
Cetero Research, San Antonio; Adiga Life Sciences, Inc.

Completed

ToleroMune Ragweed Follow up Study

Rhinoconjunctivitis | Ragweed Allergy

Canada
Circassia Limited
Cetero Research, San Antonio; Adiga Life Sciences, Inc.

Completed

Cat-PAD Follow on Study

Cat Allergy | Rhinoconjunctivitis

Canada
Nimble Science Ltd.
IGY Life Sciences

Recruiting

Evaluation of the Microbiome in Multiple Sclerosis

Multiple Sclerosis

Canada
Halucenex Life Sciences Inc.
KGK Science Inc.

Active, not recruiting

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder

Post Traumatic Stress Disorder | Treatment Resistant Disorders

Canada
Vigonvita Life Sciences

Not yet recruiting

Long-term Safety of TPN171H Tablet in Erectile Dysfunction.

Erectile Dysfunction

China
Vigonvita Life Sciences

Not yet recruiting

Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules

Healthy Subjects

China
Vigonvita Life Sciences

Recruiting

Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers

Schizophrenia

China
Recognify Life Sciences

Recruiting

A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

Schizophrenia | Cognitive Impairment | Cognitive Impairment Associated With Schizophrenia (CIAS)

United States
Achieve Life Sciences

Completed

A Study of Cytisinicline for Vaping Cessation in Adult Smokers (ORCA-V1)

Vaping | E-Cig Use

United States
Achieve Life Sciences

Completed

Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult Smokers

Smoking Cessation

Portugal
Rediscovery Life Sciences

Active, not recruiting

Study of Suramin in Subjects With Furosemide-Resistant AKI

Acute Kidney Injury

United States
Vigonvita Life Sciences

Completed

Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers

Healthy Subjects

China
Achieve Life Sciences

Completed

A Study of Cytisinicline for Smoking Cessation in Adult Smokers (ORCA-2)

Smoking Cessation

United States
Cymra Life Sciences

Completed

A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain (CYDEPS)

Pain | Back Pain | Chronic Pain | Neck Pain | Pain, Chronic | CBD | Pain, Back | Pain, Neck | THC

Australia
Vigonvita Life Sciences

Completed

Safety and Pharmacokinetics Study of Single Ascending Doses of VV116 in Healthy Volunteers

Healthy Subjects

China
Recognify Life Sciences

Completed

Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

Schizophrenia | Cognitive Impairment

United States
Wako Life Sciences

Unknown

A Protocol of the Canadian Prospective Study for Hepatocellular Carcinoma Surveillance Using Biomarkers

Cirrhosis | Chronic Liver Diseases

Canada
LG Life Sciences

Completed

Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome

Prader-Willi Syndrome

Korea, Republic of
LG Life Sciences

Completed

Observational Study to Evaluate Long-term Safety and Biodegradability of YVOIRE Volume s

Correction of Nasolabial Folds
LG Life Sciences

Completed

Observational Study to Evaluate Long-term Safety and Biodegradability of YVOIRE Classic s

Correction of Nasolabial Folds

China
LG Life Sciences

Completed

An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin

Type 2 Diabetes Mellitus

Korea, Republic of
LG Life Sciences

Completed

Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.

Growth Hormone Deficiency | Chronic Renal Failure | Turner Syndrome | Infant, Small for Gestational Age | Short Stature, Idiopathic

Korea, Republic of
LG Life Sciences

Completed

Study of LC23-1306 in Healthy Male Subjects

Acute Coronary Syndrome

Korea, Republic of
LG Life Sciences

Completed

A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX)

Rheumatoid Arthritis

Korea, Republic of
LG Life Sciences

Completed

Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)

Type 2 Diabetes Mellitus
Transparency Life Sciences

Unknown

Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Genzum Life Sciences

Completed

BE Study of Naftifine HCL

Tinea Pedis

United States, Dominican Republic

Clinical Trials Sponsored by Adiga Life Sciences

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations